
Sign up to save your podcasts
Or


We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
By Erin Harris4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn

3,447 Listeners

756 Listeners

154 Listeners

818 Listeners

113,121 Listeners

10,331 Listeners

337 Listeners

6,592 Listeners

5,610 Listeners

6,462 Listeners

85 Listeners

5,576 Listeners

11,013 Listeners

16 Listeners

1,480 Listeners